within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A01A_StomatologicalPreparations.A01AC04_Prednisolone;

model Prednisolone_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 5.6e-06,
    adminDuration = 600,
    adminMass = 40 / 1000000,
    adminCount = 1,
    Vd = 0.00062,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00038,
    k12 = 3.15e-06,
    k21 = 3.15e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Prednisolone_1</td></tr><tr><td>ATC code:</td><td>A01AC04_1</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>40</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.62</td><td>L</td></tr>
    <tr><td>clearance:</td><td>4.8</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Prednisolone is a synthetic glucocorticoid and anti-inflammatory agent widely used in the treatment of a variety of conditions including asthma, rheumatoid arthritis, autoimmune disorders, inflammatory diseases, and allergies. It is an active metabolite of prednisone and is approved and in common clinical use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model for intravenous administration in healthy adults.</p><h4>References</h4><ol><li><p>Petersen, KB, et al., &amp; Schmiegelow, K (2003). Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. <i>Cancer chemotherapy and pharmacology</i> 51(6) 465–473. DOI:<a href=\"https://doi.org/10.1007/s00280-003-0602-3\">10.1007/s00280-003-0602-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12698270/\">https://pubmed.ncbi.nlm.nih.gov/12698270</a></p></li><li><p>Honoré, PM, et al., &amp; Spapen, HD (2014). What do we know about steroids metabolism and &#x27;PK/PD approach&#x27; in AKI and CKD especially while on RRT--current status in 2014. <i>Blood purification</i> 38(2) 154–157. DOI:<a href=\"https://doi.org/10.1159/000368390\">10.1159/000368390</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25471548/\">https://pubmed.ncbi.nlm.nih.gov/25471548</a></p></li><li><p>Hill, MR, et al., &amp; Brenner, AM (1990). Monitoring glucocorticoid therapy: a pharmacokinetic approach. <i>Clinical pharmacology and therapeutics</i> 48(4) 390–398. DOI:<a href=\"https://doi.org/10.1038/clpt.1990.167\">10.1038/clpt.1990.167</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2225699/\">https://pubmed.ncbi.nlm.nih.gov/2225699</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A01AC04_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Prednisolone_1;
